- Analysis of SEP and FRAND royalties
- Antitrust counterclaims
- Business strategy
- Computer hardware and software
- Consumer and retail products
- Copyright royalties
- Industrial and commercial products
- Injunctions and exclusion orders
- International Trade Commission
- Medical devices
- Patent damages
- Patent validity
- Trade secrets
With support from Bates White, pharmaceutical manufacturer Amgen Inc. recently settled litigation with Teva Pharmaceuticals USA Inc. concerning Teva’s challenge to the validity of Amgen’s patents for Neupogen. The client obtained a favorable outcome through an agreement that prevents Teva from introducing its infringing drug in the United States before November 2013.
Dr. Douglas Bernheim testified on behalf of Amgen in Amgen v. F. Hoffman-La Roche to advise the court considering whether to grant a permanent injunction against Roche’s sales and marketing of a product that infringes Amgen’s patents. The judge issued a court order that agreed with Dr. Bernheim’s conclusions and cited his testimony extensively.
Intellectual property owners and licensees face increasingly complex challenges defending or contesting patent validity, accurately valuing IP rights, responding appropriately to infringement, and navigating the treacherous waters where IP rights and antitrust laws intersect. Bates White has assisted numerous rights holder and licensee clients with litigation or business strategy challenges that require top-tier economic analysis in the digital media, biotech, computer, consumer product, industrial, medical device, pharmaceutical and semiconductor industries, among others.
Our expertise in intellectual property includes:
- New York, NY, May 3, 2011 – May 4, 2011
- Palo Alto, CA, April 13, 2010